Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
Nab-Paclitaxel Added To Gemcitabine And Epirubicin Shows Potential As Neoadjuvant Treatment For Early Breast Cancer
http://www.medicalnewstoday.com/articles/133085.php
SAN ANTONIO - NabTM-paclitaxel (<a href="http://www.abraxane.com" target="_blank" rel="nofollow">Abraxane</a>), used in tandem with gemcitabine and epirubicin, is showing good anti-tumor activity and tolerability as neoadjuvant treatment for women with locally advanced breast cancer, according to phase II results released at the 2008 San Antonio Breast Cancer Symposium (SABCS).
Fall In Breast Cancer Rates Tied To Less Use Of Hormone Therapy
http://www.medicalnewstoday.com/articles/133064.php
A new study showed that taking menopausal hormone therapy comprising estrogen plus progestin for five years doubled a woman's risk of breast cancer, and suggested that the recent fall in breast cancer rates is predominantly due to a decrease in women having combined menopausal hormone therapy.
Novelos Therapeutics Announces Presentation Of Positive Results In Ongoing Phase 2 Neoadjuvant Breast Cancer Trial
http://www.medicalnewstoday.com/articles/133043.php
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that today the Braman Family Breast Cancer Institute at the Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine, in collaboration with Medical University of South Carolina Hollings Cancer Center, is presenting a poster highlighting further positive results from an ongoing Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer at the AACR Breast Cancer Symposium in San Antonio, TX.
Monogram Announces Presentation Of Clinical Data For The HERmark™ Breast Cancer Assay At The CTRC-AACR San Antonio Breast Cancer Symposium
http://www.medicalnewstoday.com/articles/133042.php
Monogram Biosciences, Inc. (Nasdaq:MGRM) announced that new results from a study of the predictive power of its HERmark™ Breast Cancer Assay were presented at the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.
Significant Improvement In Progression-Free Survival For Triple Negative Metastatic Breast Cancer Patients Treated With IXEMPRA™ Plus Capecitabi
http://www.medicalnewstoday.com/articles/133039.php
<a href="http://www.bms.com" target="_blank" rel="nofollow">Bristol-Myers Squibb</a> Company (NYSE:BMY) today announced new data from studies of IXEMPRA™ (ixabepilone) plus capecitabine compared to capectabine alone, including a pre-specified sub set analysis demonstrating a significant increase in progression free survival (PFS) in patients with triple negative breast cancer.
Women At High Risk Of Breast Cancer May Benefit From Alternating Mammography And MRI
http://www.medicalnewstoday.com/articles/133038.php
Magnetic resonance imaging (MRI) alternated with mammography at six-month intervals can detect breast cancers not identified by mammography alone, a research team from The University of Texas M.
Research On Tamoxifen Leads To Recommendation For CYP2D6 Gene Test
http://www.medicalnewstoday.com/articles/133035.php
Findings from a new study have prompted Mayo Clinic researchers to recommend CYP2D6 gene testing for postmenopausal women about to begin tamoxifen therapy. This data confirms that women with an inherited deficiency in the CYP2D6 gene, which is important for the metabolism of tamoxifen, have a nearly fourfold higher risk of early breast cancer recurrence compared to women who have not inherited the deficiency.
Early Stage, HER2-Positive Breast Cancer Patients At Increased Risk Of Recurrence
http://www.medicalnewstoday.com/articles/133023.php
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M.
Pfizer Announces Results From Trial Of AROMASIN In Postmenopausal Women With Hormone Sensitive Early Breast Cancer
http://www.medicalnewstoday.com/articles/133018.php
Pfizer today announced results from a first planned analysis of the TEAM (Tamoxifen, Exemestane, Adjuvant, Multicenter) trial. TEAM was originally designed in 2001 as a comparison of 5 years of upfront AROMASIN® (exemestane tablets) vs.
What Biomarkers Can Reveal About Breast Cancer
http://www.medicalnewstoday.com/articles/133009.php
As cancer researchers move away from the general use of chemotherapy and into more targeted approaches, scientists are working to discover effective ways to measure response and risk. Data presented at the CTRC-AACR San Antonio Breast Cancer Symposium illustrate the cutting edge of biomarker discovery and development.
Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset Of Low Risk HER2+ Patients
http://www.medicalnewstoday.com/articles/133008.php
Dr. Michael Knauer from the Netherlands Cancer Institute today announced data uncovering a substantial group of traditionally miscategorized low risk HER2+ patients. Agendia's highly accurate breast cancer tumor recurrence test, MammaPrint(R), was used to differentiate between patients at high and low risk for recurrence.
Breast Cancer: Patient Management, Quality Of Life And Beyond
http://www.medicalnewstoday.com/articles/133007.php
Breast cancer is a multifaceted disease requiring creative solutions for diagnosis, quality of life management and adjuvant therapies. Data presented at the CTRC-AACR San Antonio Breast Cancer Symposium explored these areas.
Tykerb™ Plus Letrozole Delays Disease Progression In Post-menopausal Women With ErbB2 Positive Metastatic Breast Cancer
http://www.medicalnewstoday.com/articles/133006.php
New results from a study in metastatic breast cancer presented today at the 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium showed that the combination of Tykerb™ (lapatinib ditosylate) plus letrozole, as a first line treatment regimen, provided a significant improvement in delaying disease progression when compared to treatment with Femara® (letrozole) alone.
Breakthrough Breast Cancer's Scottish Conversation Event
http://www.medicalnewstoday.com/articles/132972.php
Nicola Sturgeon, MSP and Deputy First Minister & Cabinet Secretary for Health & Wellbeing heard breast cancer patients talk about their experiences of breast cancer services in Scotland at Breakthrough Breast Cancer's Scottish Conversation event on Wednesday 10th December.
Most Triple-Negative Breast Cancers Express Muc-1 Target, Ireland Cancer Center Researcher Discovers
http://www.medicalnewstoday.com/articles/132965.php
Research out of the Ireland Cancer Center of University Hospitals Case Medical Center has found that the vast majority of triple negative breast cancers express the MUC-1 target. This first-of-its-kind finding, presented at the San Antonio Breast Cancer Symposium, has paved the way for an upcoming vaccine trial for patients with early stage triple negative breast cancer that could potentially prevent recurrence of this aggressive type of breast cancer.
DNA Repair Company Announces New Clinical Findings Which May Help To Guide Breast Cancer Treatment
http://www.medicalnewstoday.com/articles/132911.php
The DNA Repair Company (DNAR), an early-stage company focused on personalized approaches to cancer treatment, announced today that it has identified a promising set of protein biomarkers that may aid in the treatment of a particularly aggressive form of breast cancer.
----------------------------------------------
** CANCER / ONCOLOGY News **
Nab-Paclitaxel Added To Gemcitabine And Epirubicin Shows Potential As Neoadjuvant Treatment For Early Breast Cancer
http://www.medicalnewstoday.com/articles/133085.php
SAN ANTONIO - NabTM-paclitaxel (<a href="http://www.abraxane.com" target="_blank" rel="nofollow">Abraxane</a>), used in tandem with gemcitabine and epirubicin, is showing good anti-tumor activity and tolerability as neoadjuvant treatment for women with locally advanced breast cancer, according to phase II results released at the 2008 San Antonio Breast Cancer Symposium (SABCS).
Monogram Announces Presentation Of Clinical Data For The HERmark™ Breast Cancer Assay At The CTRC-AACR San Antonio Breast Cancer Symposium
http://www.medicalnewstoday.com/articles/133042.php
Monogram Biosciences, Inc. (Nasdaq:MGRM) announced that new results from a study of the predictive power of its HERmark™ Breast Cancer Assay were presented at the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.
Significant Improvement In Progression-Free Survival For Triple Negative Metastatic Breast Cancer Patients Treated With IXEMPRA™ Plus Capecitabi
http://www.medicalnewstoday.com/articles/133039.php
<a href="http://www.bms.com" target="_blank" rel="nofollow">Bristol-Myers Squibb</a> Company (NYSE:BMY) today announced new data from studies of IXEMPRA™ (ixabepilone) plus capecitabine compared to capectabine alone, including a pre-specified sub set analysis demonstrating a significant increase in progression free survival (PFS) in patients with triple negative breast cancer.
Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset Of Low Risk HER2+ Patients
http://www.medicalnewstoday.com/articles/133008.php
Dr. Michael Knauer from the Netherlands Cancer Institute today announced data uncovering a substantial group of traditionally miscategorized low risk HER2+ patients. Agendia's highly accurate breast cancer tumor recurrence test, MammaPrint(R), was used to differentiate between patients at high and low risk for recurrence.
Guy's And St Thomas' First Trust In UK To Use Pathwork(R) Tissue Of Origin Test For Tumours Of Unkown Origin
http://www.medicalnewstoday.com/articles/132988.php
Guy's and St Thomas' NHS Foundation Trust has announced a collaboration with Pathwork Diagnostics, a molecular diagnostics company which focuses on cancer diagnosis and treatment. Clinical and research staff at the Trust will be the first in the UK to conduct a research study which aims to establish whether the company's Pathwork® Tissue of Origin Test, a unique microarray test, will increase their ability to diagnose tumours of 'unknown origin'.
Breakthrough Breast Cancer's Scottish Conversation Event
http://www.medicalnewstoday.com/articles/132972.php
Nicola Sturgeon, MSP and Deputy First Minister & Cabinet Secretary for Health & Wellbeing heard breast cancer patients talk about their experiences of breast cancer services in Scotland at Breakthrough Breast Cancer's Scottish Conversation event on Wednesday 10th December.
Nanotubes Sniff Out Cancer Agents In Living Cells - Carbon Nanotubes Used To Monitor Chemotherapy, Detect Toxins At The Single-Molecule Level
http://www.medicalnewstoday.com/articles/132806.php
MIT engineers have developed carbon nanotubes into sensors for cancer drugs and other DNA-damaging agents inside living cells. The sensors, made of carbon nanotubes wrapped in DNA, can detect chemotherapy drugs such as cisplatin as well as environmental toxins and free radicals that damage DNA.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
Irish Advocates Call For Government To Reinstate HPV Vaccination Plan
http://www.medicalnewstoday.com/articles/132977.php
Some women's health advocates in Ireland are protesting a decision last month by Minister for Health Mary Harney to cancel the government's plan to vaccinate all 12-year-old girls against human papillomavirus, the <A href="http://www.
----------------------------------------------
** COLORECTAL CANCER News **
Colorectal Cancer: Race Gap Still Growing Among Americans
http://www.medicalnewstoday.com/articles/133104.php
A new report by a leading US cancer organization said that although progress in reducing the rate of new colorectal cancer cases and deaths is better than ever, the gap between blacks and whites is still growing, with the latest figures showing that among African Americans the death rates are about 45 per cent higher than among white Americans.
----------------------------------------------
** LUNG CANCER News **
International Tobacco Control Leaders Recognized By American Cancer Society
http://www.medicalnewstoday.com/articles/133030.php
The American Cancer Society has announced the winners of the 2009 Luther L. Terry Awards for Exemplary Leadership in Tobacco Control. The awards are named for the late United States Surgeon General Luther L.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
Genta To Appeal FDA Decision On New Drug Application For Genasense(R) In Patients With Chronic Lymphocytic Leukemia
http://www.medicalnewstoday.com/articles/133015.php
Genta Incorporated (OTCBB: GNTA.OB) announced that the Company has filed an appeal of the recent negative decision by the Food and Drug Administration's (FDA) Office of Oncology Drug Products (OODP) regarding the Company's New Drug Application (NDA) for Genta's lead oncology product, Genasense® (oblimersen sodium) Injection.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
Why Do Men Refuse Prostate Cancer Screening? Demographic Analysis In Turkey
http://www.medicalnewstoday.com/articles/132936.php
UroToday.com - Prostate cancer is one of the most common cancers in men, with a high incidence rate in Turkey. However, the early detection and diagnosis rates are considerably lower among Turkish men as compared with their counterparts in Western countries.
The Evolving Role Of Oestrogens And Their Receptors In The Development And Progression Of Prostate Cancer
http://www.medicalnewstoday.com/articles/132935.php
UroToday.com - The androgen receptor (AR) is currently the major target for prostate cancer (PCa) prevention and treatment. Nevertheless, there are multiple lines of evidence to suggest that oestrogens and their receptors are also involved in PCa development and tumor progression.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment